Strs Ohio reduced its holdings in Recro Pharma Inc (NASDAQ:REPH) by 16.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 76,400 shares of the specialty pharmaceutical company’s stock after selling 14,900 shares during the period. Strs Ohio owned approximately 0.36% of Recro Pharma worth $542,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in REPH. BlackRock Inc. lifted its holdings in Recro Pharma by 27.6% in the second quarter. BlackRock Inc. now owns 1,144,988 shares of the specialty pharmaceutical company’s stock valued at $5,747,000 after buying an additional 247,559 shares during the period. Panagora Asset Management Inc. increased its stake in Recro Pharma by 1,361.1% in the third quarter. Panagora Asset Management Inc. now owns 189,128 shares of the specialty pharmaceutical company’s stock valued at $1,345,000 after purchasing an additional 176,184 shares in the last quarter. Essex Investment Management Co. LLC increased its stake in Recro Pharma by 73.5% in the third quarter. Essex Investment Management Co. LLC now owns 252,874 shares of the specialty pharmaceutical company’s stock valued at $1,798,000 after purchasing an additional 107,125 shares in the last quarter. Renaissance Technologies LLC increased its stake in Recro Pharma by 26.0% in the third quarter. Renaissance Technologies LLC now owns 480,500 shares of the specialty pharmaceutical company’s stock valued at $3,416,000 after purchasing an additional 99,200 shares in the last quarter. Finally, Engine Capital Management LP increased its stake in Recro Pharma by 21.0% in the third quarter. Engine Capital Management LP now owns 473,484 shares of the specialty pharmaceutical company’s stock valued at $3,366,000 after purchasing an additional 82,177 shares in the last quarter. Institutional investors and hedge funds own 52.11% of the company’s stock.

Shares of REPH stock traded up $0.01 during trading hours on Monday, hitting $8.30. 529 shares of the company were exchanged, compared to its average volume of 73,255. The company has a quick ratio of 1.16, a current ratio of 1.36 and a debt-to-equity ratio of 4.04. Recro Pharma Inc has a 52 week low of $4.78 and a 52 week high of $13.05. The company has a market capitalization of $178.05 million, a price-to-earnings ratio of -4.17 and a beta of -0.31.

Several equities research analysts have commented on the stock. Zacks Investment Research downgraded shares of Recro Pharma from a “buy” rating to a “hold” rating in a research note on Saturday, November 10th. ValuEngine downgraded shares of Recro Pharma from a “buy” rating to a “hold” rating in a research note on Monday, December 3rd. Janney Montgomery Scott reaffirmed a “buy” rating and issued a $13.00 target price on shares of Recro Pharma in a research note on Thursday, January 31st. Oppenheimer set a $18.00 target price on shares of Recro Pharma and gave the company a “buy” rating in a research note on Thursday, November 8th. Finally, Piper Jaffray Companies set a $10.00 target price on shares of Recro Pharma and gave the company a “buy” rating in a research note on Thursday, November 8th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Recro Pharma presently has a consensus rating of “Buy” and a consensus price target of $13.04.

ILLEGAL ACTIVITY NOTICE: This story was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The legal version of this story can be viewed at https://www.thecerbatgem.com/2019/02/11/strs-ohio-has-542000-position-in-recro-pharma-inc-reph.html.

Recro Pharma Company Profile

Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Further Reading: QQQ ETF

Institutional Ownership by Quarter for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.